Sanofi's Eloctate, a Bioverativ buyout centerpiece, suffers on Roche's Hemlibra launch

Sanofi has been among the pharma companies hardest hit by U.S. pricing pressure in diabetes, and now, competition is taking a toll on the prized asset from its $11.6 billion Bioverativ buyout.